Vol. 45 (4): 782-789, July – August, 2019
doi: 10.1590/S1677-5538.IBJU.2018.0518
ORIGINAL ARTICLE
Mete Özkidik 1, Alper Coşkun 1, Mehmet Kazim Asutay 1, Tuncer Bahçeci 1, Nurullah Hamidi 2
1 Clinic of Urology, Şanliurfa Research and Training Hospital, Şanliurfa, Turkey; 2 Department of Urology, Ankara Atatürk Training and Research Hospital, Ankara, Turkey
ABSTRACT
Purpose: To evaluate the effi cacy and tolerability of mirabegron in females with overactive bladder (OAB) symptoms after surgical treatment for stress urinary incontinence (SUI).
Materials and Methods: The study was conducted with a prospective, randomized and double-blinded design. 62 patients over the age of 40 who met the inclusion-exclusion criterias of the study were enrolled and randomly divided into two groups as Group A (mirabegron 50mg) and B (solifenacin 5mg). Patients were compared based on efficacy of treatment [Patient Perception of Bladder Condition (PPBC) scale and micturition diaries], safety of treatment (heart rate, systolic and diastolic blood pressure, adverse events), number of micturitions per day, patient’s satisfaction status after treatment [Visual Analog Scale(VAS)] and quality of life.
Results: The mean age of the population was 48.2±3.8 years and the duration of OAB symptoms was 5.9±2.9 months. Baseline values for the mean number of micturitions, volume voided in each micturition, nocturia episodes, urgency and urgency incontinence episodes were 15.3±0.34, 128±3.88mL, 3.96±1.67, 5.72±1.35 and 4.22±0.69, respectively.
After treatment, values for these parameters were 11.7±0.29, 164.7±2.9mL, 2.25±0.6, 3.38±0.71, 2.31±0.49 respectively. Quality of life score, symptom bother score, VAS for treatment satisfaction score, PPBC score after treatment were 66.1±0.85, 43.7±0.77, 4.78±0.14, 4.78±0.14, respectively. There were no signifi cant differences between two groups on any parameter. However, mirabegron showed better tolerability than solifenacin, particularly after 6 months.
Conclusion: Mirabegron is safe, effective and tolerable in the long-term treatment of females with OAB symptoms after surgery for stress urinary incontinence.
Keywords: mirabegron [Supplementary Concept]; Urinary Bladder, Overactive; Solifenacin Succinate; Urinary Incontinence, Stress
